AUG 04, 2020 4:27 PM PDT

Erectile Dysfunction Drug Cures Critical COVID-19 Patients

WRITTEN BY: Annie Lennon

Critically ill patients who received COVID-19 drug candidate aviptadil (RLF-100) were able to make a rapid recovery from respiratory failure from COVID-19, according to pharmaceutical companies NeuroRX and Relief Therapeutics.

Typically used alongside phentolamine to treat erectile dysfunction, the first report on the drug's success comes from doctors in Houston Methodist Hospital. 

Although these early results are yet to be released, the report highlights the case of a 54-year-old man who contracted COVID-19 while receiving treatment for rejection of a double lung transplant. Within four days of treatment with RLF-100, he reportedly came off the ventilator. The companies say that similar results also came for 15 other patients treated under emergency use. 

More than this, the report supposedly highlights the rapid clearance of classic pneumonitis findings on x-rays, improved blood oxygen, and a 50% or greater average reduction in laboratory markers for inflammation by COVID-19. 

An independent research team at the Oswaldo Cruz Foundation in Rio de Janeiro, Brazil, also showed that the drug candidate was able to prevent SARS coronavirus replication in human lung cells and monocytes in Petri dishes. 

Although promising results, due to the relatively small sample size, and other limitations, Jonathon Javitt, NeuroRx CEO and Chairman remains cautious. 

"If you ask me whether this is the cure to COVID, my answer is that I don't know, but it shows promise, and I hope so," says Javitt. "Of course, this is a small number [refering to patient data so far], and of course, testing that includes patients given placebos is needed."

Last week, the US Food and Drug Administration granted the drug an Expanded Access Protocol to treat respiratory distress from COVID-19. This means that the drug can be administered on an emergency basis to patients who are too ill to join a clinical trial and pregnant women. Meanwhile, Phase II/III trials involving 70 people are still ongoing. 

 

Sources: Clinical Trial ArenaTimes of Israel

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
JUL 25, 2020
Drug Discovery & Development
New Method for Targeting The Herpes Virus
JUL 25, 2020
New Method for Targeting The Herpes Virus
A new way for treating the human herpes viruses was recently discovered by researchers at Lund University in Sweden. The ...
AUG 06, 2020
Drug Discovery & Development
How Medieval Medicine Can Conquer Modern Day Infections?
AUG 06, 2020
How Medieval Medicine Can Conquer Modern Day Infections?
One of our current global threats is antibiotic resistance.     As more biofilm-associated infections are ...
AUG 26, 2020
Cancer
NAP-6: A Potential Candidate for the Treatment of Breast Cancer
AUG 26, 2020
NAP-6: A Potential Candidate for the Treatment of Breast Cancer
The body is an amazing and complex system of pathways, all working together in harmony. However, cancer can quickly disr ...
AUG 26, 2020
Drug Discovery & Development
Can Sugar Cause A Leaky Gut?
AUG 26, 2020
Can Sugar Cause A Leaky Gut?
Can Sugar Cause A Leaky Gut? Apparently, research at the University of California San Diego School of Medicine seems to ...
SEP 08, 2020
Cardiology
Fixing Stem Cell Therapy for Heart Repair
SEP 08, 2020
Fixing Stem Cell Therapy for Heart Repair
Repairing the damage done by a heart attack has been of keen interest for decades. Some researchers think protecting the ...
SEP 01, 2020
Drug Discovery & Development
First Novel Compounds to Inhibit Cancer-Linked Enzymes
SEP 01, 2020
First Novel Compounds to Inhibit Cancer-Linked Enzymes
Researchers from the University of Michigan Rogel Cancer Center have worked on creating a therapeutic-based compound tha ...
Loading Comments...